TY - JOUR
T1 - Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma
AU - Craig, Amanda J.
AU - Garcia-Lezana, Teresa
AU - de Galarreta, Marina Ruiz
AU - Villacorta-Martin, Carlos
AU - Kozlova, Edgar G.
AU - Martins-Filho, Sebastiao N.
AU - Felden, Johann von
AU - Ahsen, Mehmet Eren
AU - Bresnahan, Erin
AU - Hernandez-Meza, Gabriela
AU - Labgaa, Ismail
AU - D’Avola, Delia
AU - Schwartz, Myron
AU - Llovet, Josep M.
AU - Sia, Daniela
AU - Thung, Swan
AU - Losic, Bojan
AU - Lujambio, Amaia
AU - Villanueva, Augusto
N1 - Publisher Copyright:
© This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
PY - 2021/6/24
Y1 - 2021/6/24
N2 - Cancer testis antigens (CTAs) are an extensive gene family with a unique expression pattern restricted to germ cells, but aberrantly reactivated in cancer tissues. Studies indicate that the expression (or re-expression) of CTAs within the MAGE-A family is common in hepatocellular carcinoma (HCC). However, no systematic characterization has yet been reported. The aim of this study is to perform a comprehensive profile of CTA de-regulation in HCC and experimentally evaluate the role of MAGEA3 as a driver of HCC progression. The transcriptomic analysis of 44 multi-regionally sampled HCCs from 12 patients identified high intra-tumor heterogeneity of CTAs. In addition, a subset of CTAs was significantly overexpressed in histologically poorly differentiated regions. Further analysis of CTAs in larger patient cohorts revealed high CTA expression related to worse overall survival and several.
AB - Cancer testis antigens (CTAs) are an extensive gene family with a unique expression pattern restricted to germ cells, but aberrantly reactivated in cancer tissues. Studies indicate that the expression (or re-expression) of CTAs within the MAGE-A family is common in hepatocellular carcinoma (HCC). However, no systematic characterization has yet been reported. The aim of this study is to perform a comprehensive profile of CTA de-regulation in HCC and experimentally evaluate the role of MAGEA3 as a driver of HCC progression. The transcriptomic analysis of 44 multi-regionally sampled HCCs from 12 patients identified high intra-tumor heterogeneity of CTAs. In addition, a subset of CTAs was significantly overexpressed in histologically poorly differentiated regions. Further analysis of CTAs in larger patient cohorts revealed high CTA expression related to worse overall survival and several.
UR - http://www.scopus.com/inward/record.url?scp=85108918129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108918129&partnerID=8YFLogxK
U2 - 10.1371/journal.pgen.1009589
DO - 10.1371/journal.pgen.1009589
M3 - Article
C2 - 34166362
AN - SCOPUS:85108918129
SN - 1553-7390
VL - 17
JO - PLoS genetics
JF - PLoS genetics
IS - 6
M1 - e1009589
ER -